TRACON Pharmaceuticals Balance Sheet Health
Financial Health criteria checks 3/6
TRACON Pharmaceuticals has a total shareholder equity of $-809.0K and total debt of $0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are $10.1M and $10.9M respectively.
Key information
0%
Debt to equity ratio
US$0
Debt
Interest coverage ratio | n/a |
Cash | US$8.56m |
Equity | -US$809.00k |
Total liabilities | US$10.91m |
Total assets | US$10.11m |
Recent financial health updates
Recent updates
Tracon Pharmaceuticals announces $35M non-dilutive debt facility
Sep 06Tracon Pharma gets FDA nod to start phase 1/2 trial of triplet combo to treat sarcoma
Aug 29Tracon GAAP EPS of -$0.31 beats by $0.05, revenue of $0M
Aug 10TRACON Pharmaceuticals announces $5M registered direct offering
Dec 29TRACON Pharma launches $8.8M direct offering
Dec 22Dosing underway for TRACON Pharma's envafolimab in mid-stage soft tissue cancer study
Dec 10Tracon Pharma files China application for envafolimab in solid tumors
Nov 16Financial Position Analysis
Short Term Liabilities: TCON has negative shareholder equity, which is a more serious situation than short term assets not covering short term liabilities.
Long Term Liabilities: TCON has negative shareholder equity, which is a more serious situation than short term assets not covering long term liabilities.
Debt to Equity History and Analysis
Debt Level: TCON is debt free.
Reducing Debt: TCON's has negative shareholder equity, so we do not need to check if its debt has reduced over time.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: Whilst unprofitable TCON has sufficient cash runway for more than 3 years if it maintains its current positive free cash flow level.
Forecast Cash Runway: TCON is unprofitable but has sufficient cash runway for more than 3 years, due to free cash flow being positive and growing by 5.6% per year.